Although previous researchers have demonstrated that GFAP in patients with higher-grade gliomas was more expressed than those with lower-grade gliomas [18], we found a different result that the protein level of GFAP was unrelated with the possibility of CDC42EP3 overexpression with the latter positively correlating with tumor pathological grading. This evidence concerns the gene CDC42EP3 and central nervous system cancer.